UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Lomustine and Bevacizumab in Progressive Glioblastoma

The New England journal of medicine, 2017-11, Vol.377 (20), p.1954-1963

2017

Link zum Volltext

Verfügbarkeit prüfen

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Acta neuropathologica, 2020-03, Vol.139 (3), p.603-608

2020

Link zum Volltext

Verfügbarkeit prüfen

Pseudoprogression of brain tumors

Journal of magnetic resonance imaging, 2018-09, Vol.48 (3), p.571-589

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

The lancet oncology, 2021-06, Vol.22 (6), p.813-823

2021

Link zum Volltext

Verfügbarkeit prüfen

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

Lancet neurology, 2010-09, Vol.9 (9), p.906-920

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

The lancet oncology, 2008-05, Vol.9 (5), p.453-461

2008

Link zum Volltext

Verfügbarkeit prüfen

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

Acta neuropathologica, 2018-04, Vol.135 (4), p.601-615

2018

Link zum Volltext

Verfügbarkeit prüfen

“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas

Neuro-oncology (Charlottesville, Va.), 2020-07, Vol.22 (7), p.936-943

2020

Link zum Volltext

Verfügbarkeit prüfen

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

Clinical cancer research, 2017-10, Vol.23 (19), p.5745-5756

2017

Link zum Volltext

Verfügbarkeit prüfen

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

Acta neuropathologica, 2010-09, Vol.120 (3), p.297-304

van den Bent, Martin J.

2010

Link zum Volltext

Verfügbarkeit prüfen

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?

Neuro-oncology (Charlottesville, Va.), 2023-04, Vol.25 (4), p.631-634

2023

Link zum Volltext

Verfügbarkeit prüfen

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

The lancet oncology, 2016-11, Vol.17 (11), p.1521-1532

2016

Link zum Volltext

Verfügbarkeit prüfen

Diffuse Infiltrating Oligodendroglioma and Astrocytoma

Journal of clinical oncology, 2017-07, Vol.35 (21), p.2394-2401

2017

Link zum Volltext

Verfügbarkeit prüfen

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

The lancet oncology, 2014-08, Vol.15 (9), p.e395-e403

2014

Link zum Volltext

Verfügbarkeit prüfen

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

The lancet oncology, 2019-02, Vol.20 (2), p.216-228

2019

Link zum Volltext

Verfügbarkeit prüfen

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

The Lancet (British edition), 2017-10, Vol.390 (10103), p.1645-1653

2017

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

Journal of neuro-oncology, 2019-08, Vol.144 (1), p.205-210

2019

Link zum Volltext

Verfügbarkeit prüfen

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

The New England journal of medicine, 2023-08, Vol.389 (7), p.589-601

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 631

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(603)
Mit Volltextzugriff
(610)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Response assessment criteria for brain metastases: proposal from the RANO group

Lomustine and Bevacizumab in Progressive Glioblastoma

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Pseudoprogression of brain tumors

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study

Diffuse Infiltrating Oligodendroglioma and Astrocytoma

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

“Finding my way in a maze while the clock is ticking”: The daily life challenges of adolescents and young adults with an uncertain or poor cancer prognosis

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Suchergebnisse filtern